TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07449702: An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis

Sponsor: Oruka Therapeutics, Inc. · Phase: PHASE2 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 240 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$1,986,600

Rescue Site Savings

+$1,315,800

Unlock Full NCT07449702 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07449702 Rescue Dossier →